• Drug Coverage
  • Hypertrophic Cardiomyopathy (HCM)
  • Vaccines: 2023 Year in Review
  • Eyecare
  • Urothelial Carcinoma
  • Women's Health
  • Hemophilia
  • Heart Failure
  • Vaccines
  • Neonatal Care
  • NSCLC
  • Type II Inflammation
  • Substance Use Disorder
  • Gene Therapy
  • Lung Cancer
  • Spinal Muscular Atrophy
  • HIV
  • Post-Acute Care
  • Liver Disease
  • Pulmonary Arterial Hypertension
  • Safety & Recalls
  • Biologics
  • Asthma
  • Atrial Fibrillation
  • Type I Diabetes
  • RSV
  • COVID-19
  • Cardiovascular Diseases
  • Breast Cancer
  • Prescription Digital Therapeutics
  • Reproductive Health
  • The Improving Patient Access Podcast
  • Blood Cancer
  • Ulcerative Colitis
  • Respiratory Conditions
  • Multiple Sclerosis
  • Digital Health
  • Population Health
  • Sleep Disorders
  • Biosimilars
  • Plaque Psoriasis
  • Leukemia and Lymphoma
  • Oncology
  • Pediatrics
  • Urology
  • Obstetrics-Gynecology & Women's Health
  • Opioids
  • Solid Tumors
  • Autoimmune Diseases
  • Dermatology
  • Diabetes
  • Mental Health

Catalyst for Payment Reform initiative launched to accelerate healthcare payment reforms

Article

Seven large employers, including six Fortune 500 companies and one state, have launched Catalyst for Payment Reform (CPR

Seven large employers, including six Fortune 500 companies and one state, have launched Catalyst for Payment Reform (CPR). CPR is an effort to help large employers work together to accelerate healthcare payment reforms.

The employers who have signed onto CPR are The Boeing Company, Delta Air Lines, Equity Healthcare, GE, the Group Insurance Commission of the Commonwealth of Massachusetts, Intel Corporation, and Wal-Mart Stores, Inc.

CPR plans to provide them with tools to assess the attributes of specific markets to determine how various reforms to payment can be most effective in those locations, and will track progress on payment reform.

“There is a lot more work that needs to be done on this front, requiring much more transparency from health plans to providers,” says Suzanne Delbanco, Ph.D., who is CPR’s executive director. “We need to create the equivalent of a bank statement for physicians and hospitals to clarify where their money comes from, how much, and why. Ideally, payment contracts will instantly align incentives for higher-quality and more cost-effective care. But as long as we are combining normal fee schedules with incentives, distinguishing the portions of each is critical to motivate behavior change.”

CPR’s plans to release tools throughout this fall, including the Market Assessment Tool and six Action Briefs that outline steps employers can take toward three types of payment reform (fee for service, bundled payments, and global payments), two types of delivery system reform (accountable care organizations and medical homes), and analyses of how the level of competition in a given market affects the rates at which purchasers and plans pay providers.

Related Videos
Video 3 - "In-Office Procedures, Over-the-Counter Options, Treatment Delays, and Costs"
Video 6 - "Safety Analysis and Interpreting Results from MAJIC-PV"
Video 5 - "Key Findings from MAJIC-PV"
Video 2 - "Traditional Treatment of Demodex Blepharitis, FDA approval, and Lotilaner Ophthalmic Solution, 0.25%"
Gabriela Hobbs, MD, an expert on polycythemia vera
Gabriela Hobbs, MD, and Timothy Mok, PharmD, BCPS, BCOP
Video 1 - "Demodex Blepharitis: Prevalence, Symptoms, Quality of Life Impact, and Diagnosis"
Video 2 - "The Role of Ruxolitinib in Managing Hydroxyurea Resistance or Intolerance"
Video 1 - "Prevalence and Impact of Hydroxyurea Intolerance or Resistance in Polycythemia Vera"
Related Content
© 2024 MJH Life Sciences

All rights reserved.